Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haplo-HCT with Post-Transplant Cyclophosphamide in Advanced Myelofibrosis
NCT03426969Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide in myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events at 100 days. Started Jan 2018; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03426969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426969.